Clinical Trials Logo

Neurotrophic Keratitis clinical trials

View clinical trials related to Neurotrophic Keratitis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04820010 Completed - Corneal Ulcer Clinical Trials

Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3

Start date: October 1, 2018
Phase:
Study type: Observational

Purpose: To evaluate the clinical outcome of patients with refractory Neurotrophic Keratopathy (NK) in stages 2 and 3 treated with topical insulin. Methods: A retrospective, observational analysis of eyes with NK in stages 2 and 3 refractory to standard medical and/or surgical treatment which were treated with topical insulin. Topical insulin (1 unit per mL) was applied 4 times a day; treatment was continued until persistent epithelial defect (PED) or ulcer resolved and then tapered accordingly. The primary outcome of the study was the complete resolution of the PED or ulcer. Best-corrected visual acuity (BCVA), days until complete resolution as well as anterior segment photographs were obtained.

NCT ID: NCT04552730 Completed - Clinical trials for Neurotrophic Keratitis

Nerve Growth Factor for the Treatment of Cornea Disease

Start date: October 14, 2020
Phase:
Study type: Observational

To determine the efficacy and safety of nerve growth factor in the treatment of limbal stem cell deficiency (LSCD) associated with neurotrophic cornea.

NCT ID: NCT04485546 Completed - Clinical trials for Neurotrophic Keratitis

Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis

DEFENDO
Start date: September 9, 2020
Phase: Phase 4
Study type: Interventional

This study is to evaluate the safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).

NCT ID: NCT02227147 Completed - Clinical trials for Neurotrophic Keratitis

Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK

Start date: February 2015
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of 20 µg/ml 6 times a day of rhNGF eye drops solution (formulation containing anti-oxidant) compared to vehicle (formulation containing anti-oxidant) given 6 times a day. The evaluation of efficacy is intended as: - complete healing of stage 2 (persistent epithelial defect) and 3 (corneal ulcer) neurotrophic keratitis (NK) as measured by the central reading center using corneal fluorescein staining, - assessing the duration of complete healing, - improvement in visual acuity and improvement in corneal sensitivity.

NCT ID: NCT01756456 Completed - Keratitis Clinical Trials

Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.

REPARO
Start date: January 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This study is aimed at assessing the safety and the efficacy of two dose regimens of recombinant human nerve growth factor (rhNGF) eye drops solution compared to vehicle for inducing a complete healing of stage 2 (persistent epithelial defect) and 3 (corneal ulcer) neurotrophic keratitis